Changes in IgE sensitization and total IgE levels over 20 years of follow-up - 03/06/16
Doi : 10.1016/j.jaci.2015.09.037
André F.S. Amaral, PhD a, ⁎ 
, Roger B. Newson, DPhil a, b, Michael J. Abramson, PhD c, Josep M. Antó, PhD d, e, f, g, Roberto Bono, PhD h, Angelo G. Corsico, PhD i, Roberto de Marco, PhD j, Pascal Demoly, MD k, Bertil Forsberg, PhD l, Thorarinn Gislason, PhD m, n, Joachim Heinrich, PhD o, p, Ismael Huerta, MD q, Christer Janson, PhD r, Rain Jõgi, PhD s, Jeong-Lim Kim, PhD t, José Maldonado, MD u, Jesús Martinez-Moratalla Rovira, MD v, Catherine Neukirch, MD w, x, Dennis Nowak, MD y, Isabelle Pin, MD z, aa, bb, Nicole Probst-Hensch, PhD cc, dd, Chantal Raherison-Semjen, PhD ee, Cecilie Svanes, PhD ff, gg, Isabel Urrutia Landa, PhD hh, Ronald van Ree, PhD ii, Serge A. Versteeg, BSc jj, Joost Weyler, PhD kk, Jan-Paul Zock, PhD d, f, g, Peter G.J. Burney, MD a, Deborah L. Jarvis, MD a
, Roger B. Newson, DPhil a, b, Michael J. Abramson, PhD c, Josep M. Antó, PhD d, e, f, g, Roberto Bono, PhD h, Angelo G. Corsico, PhD i, Roberto de Marco, PhD j, Pascal Demoly, MD k, Bertil Forsberg, PhD l, Thorarinn Gislason, PhD m, n, Joachim Heinrich, PhD o, p, Ismael Huerta, MD q, Christer Janson, PhD r, Rain Jõgi, PhD s, Jeong-Lim Kim, PhD t, José Maldonado, MD u, Jesús Martinez-Moratalla Rovira, MD v, Catherine Neukirch, MD w, x, Dennis Nowak, MD y, Isabelle Pin, MD z, aa, bb, Nicole Probst-Hensch, PhD cc, dd, Chantal Raherison-Semjen, PhD ee, Cecilie Svanes, PhD ff, gg, Isabel Urrutia Landa, PhD hh, Ronald van Ree, PhD ii, Serge A. Versteeg, BSc jj, Joost Weyler, PhD kk, Jan-Paul Zock, PhD d, f, g, Peter G.J. Burney, MD a, Deborah L. Jarvis, MD a a Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College, London, United Kingdom
b Department of Primary Care and Public Health, School of Public Health, Imperial College, London, United Kingdom
c School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia
d Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
e IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
f Universitat Pompeu Fabra (UPF), Barcelona, Spain
g CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
h Department of Public Health and Pediatrics, University of Turin, Turin, Italy
i Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation–University of Pavia, Pavia, Italy
j Unit of Epidemiology and Medical Statistics, Department of Public Health and Community Medicine, University of Verona, Verona, Italy
k Department of Pulmonology, Division of Allergy, Arnaud de Villeneuve Hospital, CHU Montpellier, and EPAR Team–UMR-S 1136 INSERM, Paris, France
l Division of Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
m Faculty of Medicine, University of Iceland, Reykjavik, Iceland
n Department of Respiratory Medicine and Sleep, Landspitali–The National University Hospital of Iceland, Reykjavik, Iceland
o Institute of Epidemiology I, Helmholtz Zentrum, Munich, Germany
p Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner City Clinic, University Hospital Munich, Ludwig-Maximilians-Universität of Munich, Munich, Germany
q Epidemiological Surveillance Section, Directorate General of Public Health, Department of Health of Asturias, Oviedo, Spain
r Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden
s Tartu University Hospital, Lung Clinic, Tartu, Estonia
t Department of Publich Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
u Unit of Clinical Management of Pneumology and Allergy, University Hospital of Huelva, Huelva, Spain
v Unit of Pneumology, University Hospital of Albacete, Albacete, Spain
w INSERM UMR1152, Paris, France
x Université Paris Diderot Paris 7, UMR1152, Paris, France
y Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner City Clinic, University Hospital Munich, Ludwig-Maximilians-Universität of Munich, and the German Center for Lung Research, Munich, Germany
z Pédiatrie, Pole Couple Enfants, CHU de Grenoble, Grenoble, France
aa INSERM U823, Institut Albert Bonniot, Grenoble, France
bb Université Joseph Fourier, Grenoble, France
cc Swiss Tropical and Public Health Institute, Basel, Switzerland
dd University of Basel, Basel, Switzerland
ee INSERM U897, Institute of Public health and Epidemiology, Bordeaux University, Bordeaux, France
ff Centre for International Health, University of Bergen, Bergen, Norway
gg Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway
hh Department of Pneumology, Galdakao Hospital, Galdakao, Spain
ii Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
jj Department of Experimental Immunology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
kk Epidemiology and Social Medicine and the StatUA Statistics Centre, University of Antwerp, Antwerp, Belgium
∗Corresponding author: André F. S. Amaral, PhD, Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Building, 1B Manresa Rd, London SW3 6LR, United Kingdom.Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Building, 1B Manresa Rd, London SW3 6LRUnited Kingdom
Abstract |
Background |
Cross-sectional studies have reported a lower prevalence of sensitization in older adults, but few longitudinal studies have examined whether this is an aging or a year-of-birth cohort effect.
Objective |
We sought to assess changes in sensitization and total IgE levels in a cohort of European adults as they aged over a 20-year period.
Methods |
Levels of serum specific IgE to common aeroallergens (house dust mite, cat, and grass) and total IgE levels were measured in 3206 adults from 25 centers in the European Community Respiratory Health Survey on 3 occasions over 20 years. Changes in sensitization and total IgE levels were analyzed by using regression analysis corrected for potential differences in laboratory equipment and by using inverse sampling probability weights to account for nonresponse.
Results |
Over the 20-year follow-up, the prevalence of sensitization to at least 1 of the 3 allergens decreased from 29.4% to 24.8% (−4.6%; 95% CI, −7.0% to −2.1%). The prevalence of sensitization to house dust mite (−4.3%; 95% CI, −6.0% to −2.6%) and cat (−2.1%; 95% CI, −3.6% to −0.7%) decreased more than sensitization to grass (−0.6%; 95% CI, −2.5% to 1.3%). Age-specific prevalence of sensitization to house dust mite and cat did not differ between year-of-birth cohorts, but sensitization to grass was most prevalent in the most recent ones. Overall, total IgE levels decreased significantly (geometric mean ratio, 0.63; 95% CI, 0.58-0.68) at all ages in all year-of-birth cohorts.
Conclusion |
Aging was associated with lower levels of sensitization, especially to house dust mite and cat, after the age of 20 years.
Le texte complet de cet article est disponible en PDF.Key words : Allergens, sensitization, cohort study, epidemiology, IgE, longitudinal analysis, aging, immunosenescence
Abbreviations used : ECRHS, GM
Plan
| Support was as follows: Australia (Melbourne): Allen and Hanbury's and the National Health and Medical Research Council. Belgium (Antwerp City and Antwerp South): the Belgian Science Policy Office, National Fund for Scientific Research (G.0402.00), University of Antwerp, Flemish Health Ministry, and Research Foundation of Flanders (G.0.410.08.N.10). Estonia (Tartu): the Estonian Science Foundation (nos. 1088 4350) and Estonian Ministry of Education (SF0180060s09). France: Ministère de la Santé, Glaxo France, Insitut Pneumologique d'Aquitaine, Contrat de Plan Etat-Région Languedoc-Rousillon, CNMATS, CNMRT (90MR/10, 91AF/6), Ministre Delegué de la Santé, RNSP, GSF, and Programme Hospitalier de Recherche Clinique National 2010. France (Bordeaux): Institut Pneumologique d’Aquitaine and INSERM U897–Université Bordeaux Segalen. France (Grenoble): Direction de la Recherche Clinique de Grenoble 2000 (no. 2610), Ministère de l’Emploi et de la Solidarité, Direction Générale de la Sante, CHU Grenoble, Comite des Maladies Respiratoires de l’Isere, and Comité Scientifique AGIRadom 2011. France (Montpellier): Aventis and Direction Régionale des Affaires Sanitaires et Sociales Languedoc-Roussillon. France (Paris): Ministère de l’Emploi et de la Solidarité, Direction Générale de la Sante, Union Chimique Belge-Pharma, Aventis, Glaxo France, Agence Nationale de la Santé, Région Ile de France, and Domaine d’intérêt majeur. Germany: Bundesminister für Forschung und Technologie. Germany (Erfurt): DFG—German Research Foundation (FR1526/1-1, HE 3294/10-1). Germany (Hamburg): DFG—German Research Foundation (MA 711/4-1, NO 262/7-1). Iceland (Reykjavik): Icelandic Research Council, Icelandic University Hospital Fund, Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation (California), Orkuveita Reykjavikur (geothermal plant), and Vegagerðin (Icelandic Road Administration [ICERA]). Italy: Ministero dell'Università e della Ricerca Scientifica e Tecnologica, CNR, Regione Veneto (RSF381/05.93), National Board of Health, and CHIESI. Italy (Pavia): GlaxoSmithKline Italy and Local University Funding for Research, 1998 and 1999. Italy (Turin): Azienda Sanitaria Locale 4 Regione Piemonte, Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico—Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, Department of Public Health and Pediatrics; University of Turin, Unit of Respiratory Medicine, National Health Service, ASL TO2. Italy (Verona): Glaxo Wellcome Spa, Fondazione Cariverona, and Education Ministry (MIUR); Norway (Bergen): Norwegian Research Council (no. 101422/310, no. 214123), Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, Norway Research Fund, Western Norway Regional Health Authorities (no. 911631), and the Bergen Medical Research Foundation. Spain: Ministerio de Sanidad y Consumo FIS (no. 91/0016060/00E-05E, no. 93/0393, no. 97/0035-01, no. 99/0034-01, no. 99/0034-02). Spain (Albacete): Hospital General de Albacete, Hospital Universitario de Albacete, Consejeria de Sanidad, and FIS (PS09/02457). Spain (Barcelona): Sociedad Espanola de Neumologia y Cirugia Toracica, Public Health Service (R01 HL62633-01), Consell Interdepartamental de Recerca i Innovacio Tecnologica (no. 1999SGR-00241), Instituto de Salud Carlos III, Red de Centros de Epidemiologia y Salud Publica (C03/09), Red de Bases moleculares y fisiologicas de las Enfermedades Respiratorias (C03/011), Red de Grupos Infancia y Medio Ambiente (G03/176), and FIS (PS09/00716). Spain (Galdakao): Basque Health Department and FIS (no. 09/01511). Spain (Huelva): Hospital General Juan Ramón Jiménez, FIS (PS09/02185), and Servicio Andaluz de Salud. Spain (Oviedo): Consejeria de Sanidad Principado de Asturias, FIS (PS09/03190). Sweden (Gothenburg, Umeå, and Uppsala): the Swedish Medical Research Council, Swedish Heart-Lung Foundation, Swedish Association against Asthma and Allergy, Swedish Cancer and Allergy Foundation, and Swedish Council for Working Life and Social Research. Sweden (Umeå): Also received funding from a Vasterbotten Country Council ALF grant. Switzerland (Basel): the Swiss National Science Foundation (no. 33CS30-148470/1, no. 33CSCO-134276/1, no. 33CSCO-108796, no. 324730-135673, no. 3247BO-104283, no. 3247BO-104288, no. 3247BO-104284, no. 3247-065896, no. 3100-059302, no. 3200-052720, no. 3200-042532, no. 4026-028099, PMPDP3-129021/1, PMPDP3-141671/1); the Federal Office for the Environment; the Federal Office of Public Health; the Federal Office of Roads and Transport; the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zürich; the Swiss Lung League; the canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino, Valais, Graubünden, and Zurich; Stiftung ehemals Bündner Heilstätten; SUVA; Freiwillige Akademische Gesellschaft; UBS Wealth Foundation; Talecris Biotherapeutics GmbH; Abbott Diagnostics; the European Commission (no. 018996–GABRIEL); and the Wellcome Trust (WT084703MA). United Kingdom: Asthma UK (formerly known as National Asthma Campaign), Department of Health, South Thames Regional Health Authority, and the Medical Research Council (G0901214/1). The coordination of the European Community Respiratory Health Survey (ECRHS) I and ECRHS II was supported by the European Commission. The coordination of ECRHS III was supported by the Medical Research Council (G0901214/1). |
|
| Disclosure of potential conflict of interest: A. F. S. Amaral receives research funding from the Medical Research Council. M. J. Abramson receives research support from E.H.Walters & M.Abramson, Pfizer, and Boehringer Ingelheim and receives consulting fees from AstraZeneca and travel support from Boehringer Ingelheim and Sanofi. P. Demoly receives consulting fees from ALK-Abelló, Circassia, Stallergenes, Allergopharma, Chiesi, Thermo Fisher Scientific, Medam Menarini, AstraZeneca, Pierre Fabra Mediacament, and DBV. R. Jõgi receives research support from the Estonian Research Council and receives consulting and lecture fees from Boehringer, Novartis, and GlaxoSmithKline and travel support from GlaxoSmithKline and Boehringer. C. Neukirch receives consulting fees and travel support from ALK-Abelló and Stallergenes. D. Nowak receives speaker fees from Mundipharma. I. Pin receives lecture fees from Novartis and MSD and travel support from GlaxoSmithKline, TEVA, and Novartis. R. van Ree receives consulting fees from HAL Allergy BV and speaker fees from Thermo Fisher Scientific. J.-P. Zock receives research support from FIS, Health Institute Carlos III, and the Spanish Ministry of Health. P. G. J. Burney serves on the Novartis Advisory Board. D. L. Jarvis receives research support from the Medical Research Council. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2015
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 137 - N° 6
P. 1788 - juin 2016 Retour au numéro
Article précédent
- Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases
- Hamoud Al-Mousa, Mohamed Abouelhoda, Dorota M. Monies, Nada Al-Tassan, Abdulaziz Al-Ghonaium, Bandar Al-Saud, Hasan Al-Dhekri, Rand Arnaout, Saleh Al-Muhsen, Nazema Ades, Sahar Elshorbagi, Sulaiman Al Gazlan, Farrukh Sheikh, Majed Dasouki, Lina El-Baik, Tanzeil Elamin, Amal Jaber, Omnia Kheir, Mohamed El-Kalioby, Shazia Subhani, Eman Al Idrissi, Mofareh Al-Zahrani, Maryam Alhelale, Noukha Alnader, Afaf Al-Otaibi, Rana Kattan, Khalid Al Abdelrahman, Muna M. Al Breacan, Faisal S. Bin Humaid, Salma Majid Wakil, Fadi Alzayer, Haya Al-Dusery, Tariq Faquih, Safa Al-Hissi, Brian F. Meyer, Abbas Hawwari
- Airway lipoxin A4/formyl peptide receptor 2–lipoxin receptor levels in pediatric patients with severe asthma
- Rosalia Gagliardo, Delphine Gras, Stefania La Grutta, Pascal Chanez, Caterina Di Sano, Giusy D. Albano, Isabelle Vachier, Angela M. Montalbano, Giulia Anzalone, Anna Bonanno, Loredana Riccobono, Mark Gjomarkaj, Mirella Profita
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?